Adoptive transfer of TCRAβ-Tregs in AD mouse model

Validation Score: 0.900 Price: $0.50 Alzheimer's disease transgenic mice expressing chimeric mouse-human APP and mutant human presenilin-1 Status: proposed

What This Experiment Tests

Validation experiment designed to validate causal mechanisms targeting APP, PSEN1 in transgenic mice expressing chimeric mouse-human APP and mutant human presenilin-1. Primary outcome: amyloid load reduction and cognitive improvement

Description

This experiment tested the therapeutic efficacy of engineered TCRAβ-Tregs in a transgenic mouse model of Alzheimer's disease. Mice expressing chimeric mouse-human amyloid precursor protein and mutant human presenilin-1 received adoptive transfer of the engineered TCRAβ-Tregs. The study measured multiple outcomes including behavioral performance, immune responses, and immunohistochemical markers. Key findings included sustained immune suppression, reduced microglial activation, decreased amyloid loads, and improved cognitive functions. 18F-fluorodeoxyglucose labeling was used to track the TCRAβ-Tregs, demonstrating their ability to home to the brain and provide antigen-specific targeting. The results showed that TCRAβ-Tregs could reduce amyloid burden, restore brain homeostasis, and improve learning and memory compared to controls.

TARGET GENE
APP, PSEN1
MODEL SYSTEM
transgenic mice expressing chimeric mouse-human APP and mutant human presenilin-1
ESTIMATED COST
$0
TIMELINE
0 months
PATHWAY
amyloid processing pathway, neuroinflammation, T cell regulation
SOURCE
extracted_from_pmid_38111016
PRIMARY OUTCOME
amyloid load reduction and cognitive improvement

Scoring Dimensions

Info Gain 0.00 (25%) Feasibility 0.00 (20%) Hyp Coverage 0.00 (20%) Cost Effect. 0.00 (15%) Novelty 0.00 (10%) Ethical Safety 0.00 (10%) 0.900 composite

📖 Wiki Pages

PSEN1 (Redirect)redirectAPP Amyloid Pathway in Alzheimer's DiseasemechanismPSEN1 Mutations in Alzheimer's DiseasediseaseAPP GenegenePSEN1 — Presenilin 1geneAPP→Amyloid-beta→Plaque→Alzheimer's Disease CausalpathwayAPP Dutch Mutation (APP Dutch)diseasePSEN1-Mutant NeuronscellAPP-Overexpressing NeuronscellAPP Arctic Mutation (APP Arctic)diseaseAPP — Amyloid Precursor ProteingeneAPP Flemish Mutation (APP Flemish)diseaseAPP Swedish Mutation (APPswe)mutationAPP Gene Dosage Reduction Therapy for Down SyndromideaAPP-BACE1-Fe65 Complexmechanism

Protocol

  • Establish transgenic mice expressing chimeric mouse-human APP and mutant human presenilin-1 cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for APP, PSEN1, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure amyloid load reduction and cognitive improvement together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4.
  • ...

    Expected Outcomes

  • The intervention targeting APP, PSEN1 shifts amyloid load reduction and cognitive improvement in the predicted direction relative to the matched control arm.
  • Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects.
  • The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.
  • Success Criteria

    • Prespecified primary endpoint (amyloid load reduction and cognitive improvement) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study.
    • The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset.
    • Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.

    Related Hypotheses (5)

    Selective Cholinergic Protection via APP Pathway Modulation0.629
    TREM2-mediated microglial tau clearance enhancement0.618
    LRP1-Dependent Tau Uptake Disruption0.600
    Extracellular Vesicle Biogenesis Modulation0.582
    Trans-Synaptic Adhesion Molecule Modulation0.544

    Debate History (0)

    No debates yet

    Experiment Results (0)

    No results recorded yet. Use POST /api/experiments/{id}/results to record a result.